Company Overview of Kinex Pharmaceuticals, Inc.
Kinex Pharmaceuticals, Inc., a biotechnology company, develops and commercializes therapies for cancer and immunomodulatory diseases. Its products include Oraxol, an oral formulation of paclitaxel for oral delivery of paclitaxel when combined with HM30181, an absorption enhancer and P-glycoprotein pump inhibitor; and Oratecan, an oral formulation of Irinotecan for oncology indications, such as colorectal cancers. The company’s products also include KX01 (KX2-391), a synthetic, orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization; and KX02 (KX2-361), a dual Src/pre-tubulin inhibitor and a small molecule drug that shows potent inhibitory acti...
701 Ellicott Street
Buffalo, NY 14203
Founded in 2003
Key Executives for Kinex Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Co-Founder and Chief Scientific Officer
Chief Operating Officer and Director
Compensation as of Fiscal Year 2014.
Kinex Pharmaceuticals, Inc. Key Developments
Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in Phase 1 Clinical Study
Jan 20 15
Kinex Pharmaceuticals announced that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas. KX2-391 (KX01), a dual Src/pre-tubulin inhibitor, is a small molecule drug that has excellent skin penetration when formulated as a topical ointment. The pre-tubulin activity causes hyperproliferating cells to undergo apoptosis due to a disruption of the tubulin dynamics needed for these cells to pass through mitosis. Actinic Keratosis (AK) is a very common skin disease that appears as rough, dry, scaly patches or growths that form on the skin when the skin is badly damaged by ultraviolet rays from the sun or through indoor tanning. Ultraviolet rays can cause damage to DNA and RNA leading to keratinocyte mutations and uncontrolled growth. Reduction of the tumor suppressor p53 level has also been implicated in the unchecked proliferation of dysplastic keratinocytes. KX2-391 also potently increases p53 levels during unchecked proliferation thereby potentially addressing the dysregulation of p53 in AK.
Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in A Phase 1 Clinical Study
Dec 24 14
Kinex Pharmaceuticals announced that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute. KX2-361 (KX02), a dual src/pre-tubulin inhibitor, is a small molecule drug that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including those that are resistant to Temozolomide (T98G), the most widely used chemotherapy for the treatment of malignant glioma. In a well-established brain tumor mouse model, KX2-361 consistently clears brain tumors after 4 weeks of therapy, in 30-60% of treated animals. These studies showed that KX2-361 induced significant necrosis compared to Temodar, and the treated animals also generated an immune response to the glioblastoma tumor cells. Pharmacokinetic studies have demonstrated that KX2-361 is absorbed orally and has approximately 75% penetration into brain tissue from plasma. Kinex Pharmaceuticals has also received Orphan Drug designation for KX2-361 for the treatment of gliomas, which are the most common and aggressive form of brain cancer. A Phase 1 clinical trial for KX2-361 has commenced at Roswell Park Cancer Institute and the Cleveland Clinic. A third site has been identified and will initiate during the fourth quarter of 2014. Dosing of the first patient has taken place at Roswell Park Cancer Institute where enrollment is expected to be robust based on the unique mechanism of action of this drug as well as the pre-clinical data that has been generated.
Kinex Pharmaceuticals Appoints Flint Besecker as Chief Operating Officer
Dec 17 14
Kinex Pharmaceuticals announced that Mr. Flint Bese cker has been appointed Chief Operating Officer of the company. Mr. Besecker will have additional responsibility over Kinex's emerging global operating platforms in addition to all corporate business matters reporting to Kinex's Chief Executive Officer, Dr. Johnson Lau. More recently, Flint served as Chief Business Officer and has been Executive Vice-President and Chief Financial Officer of Kinex since July 2013 and a Board member since 2011.
Similar Private Companies By Industry
Recent Private Companies Transactions